This is a demo store. No orders will be fulfilled.

IRAK4-IN-22 - 98%, high purity , CAS No.2170694-05-8

    Grade & Purity:
  • ≥98%
In stock
Item Number
I650645
Grouped product items
SKU Size
Availability
Price Qty
I650645-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$400.90
I650645-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$680.90
I650645-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,350.90

Basic Description

Specifications & Purity ≥98%
Biochemical and Physiological Mechanisms IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 3 and 17 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.10 µM) and can be used in studies of autoi
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC 50 values of 3 and 17 nM for IRAK4 and TAK1 , respectively. IRAK4-IN-21 effectively inhibits IL-23 production ( IC 50 =0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

In Vitro

IRAK4-IN-21 (a 4-fold serial dilution from 10 µM; 1 h) decreases the levels of IL-23 (in THP-1 and DC cells), IL-6 (in HUVEC cells) and MIP-1β (in human whole blood). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: THP-1, DC cells (are primed with IFN-γ) Concentration: 10 µM (a 4-fold serial dilution from 10 µM) Incubation Time: 1 h (pre-incubate) Result: Inhibited the levels of IL-23 in the supernatant of THP-1 and DC cells with IC 50 of 0.10 and 0.11 µM, respectively. Cell Viability AssayCell Line: HUVEC cells (IL-1β-stimulated) Concentration: 10 µM (a 4-fold serial dilution from 10 µM) Incubation Time: 1 h (pre-incubate) Result: Inhibited the level of IL-6 in the supernatant of HUVEC cells with an IC 50 of 0.11 µM. Cell Viability AssayCell Line: Human whole blood (IL-1β-stimulated) Concentration: 10 µM (a 4-fold serial dilution from 10 µM) Incubation Time: 1 h (pre-incubate) Result: Inhibited the level of MIP-1β in the human whole blood with an IC 50 of 0.51 µM.

In Vivo

IRAK4-IN-21 (75 mg/kg; p.o.; single) shows moderate efficacy in acute animal model studies for the inhibition of IL-6 production . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c mice (acute mouse model; IL-1β-stimulated) . Dosage: 75 mg/kg Administration: Oral administration; single (pre-treat). Result: Showed 64% inhibition of IL-6, plasma concentrations was 6817 ng/mL at 0.5 h and 700 ng/mL at 2 h.

Form:Solid

Names and Identifiers

Smiles O=C([C@H]1[C@@H](C2)C=C[C@@H]2[C@H]1NC3=NC(NC4=CC=CC(C(N5CCCC5)=O)=C4)=NC=C3C6=CC(F)=NC=C6)N
Molecular Weight 513.57

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.